Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 309 | 46 | 249 |
| Samples | 223 | 35 | 180 |
| Peptides | 188 | 31 | 157 |
Function
CD4 · CD4 molecule
This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, May 2020].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 174 amino-acid changes on canonical ENST00000011653 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CD4 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CD4 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 15/612 2% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 8/210 4% | 37/1899 2% |
| Colorectal Carcinoma | 3/143 2% | 34/3239 1% |
| Other Solid Cancers | 2/94 2% | 14/1515 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Gastric Carcinoma | 0/74 0% | 14/1809 1% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 11/1390 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 5/810 1% |
| Other Sarcomas | 1/69 1% | 4/699 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Thyroid Gland Carcinoma | 3/45 7% | 4/1592 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Neuroblastoma | 0/87 0% | 3/1331 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
Mutation Distribution
Where CD4 is mutated · all tissues, split by cell line vs tissue
How many mutations in CD4 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 309 mutations in CD4
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|